摘要
The epidemic of corona virus disease 2019(COVID-19)caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern(VOCs)has been ongoing for over 3 years.Antibody therapies encompassing convalescent plasma,hyperimmunoglobulin,and neutralizing monoclonal antibodies(mAbs)applied in passive immunotherapy have yielded positive outcomes and played a crucial role in the early COVID-19 treatment.In this review,the development path,action mechanism,clinical research results,challenges,and safety profile associated with the use of COVID-19 convalescent plasma,hyperimmunoglobulin,and mAbs were summarized.In addition,the prospects of applying antibody therapy against VOCs was assessed,offering insights into the coping strategies for facing new infectious disease outbreaks.
